Patterson Companies Company Profile (NASDAQ:PDCO)

Patterson Companies trades on the NASDAQ under the ticker symbol "PDCO."

Patterson Companies declared a quarterly dividend on Tuesday, June 13th. Shareholders of record on Friday, July 14th will be given a dividend of $0.26 per share on Friday, July 28th. This represents a $1.04 dividend on an annualized basis and a dividend yield of 2.85%. The ex-dividend date is Wednesday, July 12th. View Patterson Companies' Dividend History.

Patterson Companies, Inc. (NASDAQ:PDCO) issued its quarterly earnings results on Thursday, May, 25th. The company reported $0.69 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.65 by $0.04. The company earned $1.45 billion during the quarter, compared to analysts' expectations of $1.46 billion. Patterson Companies had a return on equity of 15.94% and a net margin of 3.06%. The business's quarterly revenue was down .6% on a year-over-year basis. During the same period last year, the company posted $0.77 earnings per share. View Patterson Companies' Earnings History.

Patterson Companies is scheduled to release their next quarterly earnings announcement on Thursday, August, 24th 2017. View Earnings Estimates for Patterson Companies.

Patterson Companies updated its FY18 earnings guidance on Thursday, June, 1st. The company provided earnings per share (EPS) guidance of $2.25-2.40 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.33.

10 analysts have issued twelve-month target prices for Patterson Companies' stock. Their forecasts range from $34.00 to $50.00. On average, they anticipate Patterson Companies' stock price to reach $42.50 in the next year. View Analyst Ratings for Patterson Companies.

Here are some recent quotes from research analysts about Patterson Companies stock:

• 1. UBS AG analysts commented, "tough to fill" even with new product introductions — a view that is shared among others on the Street.The loss of Sirona could also generate further market share losses in consumables sales, which are expected to remain in the low-single digit range, Cherny continued. As such, it is not clear at this point in time if the company will be able to accelerate recent EBIT growth, especially when factoring in expectations for further EBIT margin pressures from the Animal Health mix shift.Meanwhile, Patterson hasn't yet brought in a permanent CEO, and once an executive is appointed, they will need to immediately implement a sales force rebuild, the analyst added. Also, the ongoing ERP investment (Enterprise Resource Planning) and roll-out continues to be an overhang and needs to be managed properly to fully take advantage of any new opportunity.While these issues are indeed fixable and the hiring of a new CEO could "pivot the company in a more sustainable direction," (7/11/2017)
• 2. According to Zacks Investment Research, "The Patterson Companies reported a mixed fourth quarter of fiscal 2017, wherein adjusted earnings beat the Zacks Consensus Estimate, while revenues missed the same. On the positive side, we str upbeat about the company’s Animal Health segment. Additionally, the company offers a wide range of consumable supplies, equipment and software, and value-added services. Of the negatives, Patterson Companies’ Dental platform sales dropped significantly on a year-over-year basis in the fourth quarter. The U.S. dental products distribution industry is highly competitive, indicating looming concerns ahead. Share price movement in the past six months has been disappointing, trading below the broader industry. It has been observed that an unfavorable foreign exchange rate and higher operating expenses are the major concerns for the company. Finally, the stock’s overvaluation reflects a relatively dull scenario that might be a cause for investors’ concern." (5/31/2017)
• 3. Stifel Nicolaus analysts commented, "Our accompanying survey diligence (n = 72) highlights near-term market share concerns for Patterson's dental business amid turnover in the company's sales reps and decision not to extend exclusivity for Sirona equipment (largely CEREC and imaging) after September 2017. Longer term, our findings suggest pressure from alternative sources of supply (e.g., Amazon) is creeping into the equation and the prominence of GPOs seems likely to increase, which in short, could shift purchasing power toward the dental practices and curtail future growth. Additionally, competition for large DSO contracts is heating up as evidenced by the recent Patterson / Heartland deal. While Dental and Veterinary continue to offer compelling end market dynamics, the headwinds detailed in our survey keep us on the sidelines with the belief that the lower multiples recently ascribed to these businesses may become the new normal. We reiterate our Hold rating on PDCO and lower our target price to $39 (from $41)." (1/30/2017)

Some companies that are related to Patterson Companies include ABIOMED (ABMD), William Demant Holdings (WILYY), Seattle Genetics (SGEN), West Pharmaceutical Services (WST), DexCom (DXCM), Bio-Rad Laboratories (BIO), Envision Healthcare Corporation (EVHC), Bioverativ (BIVV), TESARO (TSRO), Ionis Pharmaceuticals (IONS), Icon Plc (ICLR), athenahealth (ATHN), United Therapeutics Corporation (UTHR), Dr. Reddy's Laboratories Ltd (RDY), Valeant Pharmaceuticals International (VRX), Hill-Rom Holdings (HRC), Charles River Laboratories International (CRL) and PRA Health Sciences (PRAH).

Patterson Companies' management team includes the folowing people:

• James W. Wiltz, Interim President, Interim Chief Executive Officer, Director
• Ann B. Gugino, Chief Financial Officer, Executive Vice President, Treasurer
• David G. Misiak, President - Patterson Dental North America
• Kevin Pohlman, Interim President - Patterson Animal Health
• Kelly A. Baker, Chief Human Resource Officer
• Les B. Korsh, Vice President, General Counsel and Secretary
• John D. Buck, Non-Executive Chairman of the Board
• Scott P. Anderson, Director
• Alex N. Blanco, Director
• Jody H. Feragen, Independent Director

Patterson Companies' stock is owned by many different of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.74%), BlackRock Inc. (6.68%), State Street Corp (4.36%), Fairpointe Capital LLC (3.71%), Wells Fargo & Company MN (3.16%) and Kayne Anderson Rudnick Investment Management LLC (1.72%). Company insiders that own Patterson Companies stock include Ann B Gugino, Ellen A Rudnick, James W Wiltz, Jerome E Thygesen, John D Buck and Scott P Anderson. View Institutional Ownership Trends for Patterson Companies.

Patterson Companies' stock was sold by a variety of institutional investors in the last quarter, including Nuance Investments LLC, Westwood Holdings Group Inc., BlackRock Inc., Farr Miller & Washington LLC DC, Riverbridge Partners LLC, Epoch Investment Partners Inc., Wells Fargo & Company MN and State of Wisconsin Investment Board. Company insiders that have sold Patterson Companies stock in the last year include Ann B Gugino, Ellen A Rudnick, James W Wiltz and Scott P Anderson. View Insider Buying and Selling for Patterson Companies.

Patterson Companies' stock was bought by a variety of institutional investors in the last quarter, including Thompson Siegel & Walmsley LLC, Heartland Advisors Inc., Gotham Asset Management LLC, AXA, Shapiro Capital Management LLC, Fisher Asset Management LLC, Schroder Investment Management Group and Parametric Portfolio Associates LLC. View Insider Buying and Selling for Patterson Companies.

Shares of Patterson Companies can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Patterson Companies stock can currently be purchased for approximately $36.45.